uniQure (NASDAQ:QURE) Given New $80.00 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its price target for uniQure (NASDAQ:QURE) from $47.00 to $80.00, indicating a potential upside of 68.42% from the company's previous close.
• Other analysts, including Stifel Nicolaus and HC Wainwright, have also upgraded their ratings and price targets on uniQure, reflecting a trend of positive sentiment among market analysts.
• uniQure's recent earnings report showed that it surpassed consensus estimates, with a revenue of $5.26 million for the quarter, exceeding expectations of $5.00 million.

uniQure (NASDAQ:QURE - Get Free Report) had its target price raised by research analysts at Cantor Fitzgerald from $47.00 to $80.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. Cantor Fitzgerald's price target suggests a potential upside of 68.42% from the company's previous close.

A number of other research analysts have also weighed in on QURE. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Stifel Nicolaus raised their price target on shares of uniQure from $30.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of uniQure in a research note on Wednesday. Mizuho raised shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target on the stock in a research note on Thursday, August 14th. Finally, Chardan Capital raised their price target on shares of uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $55.45.

uniQure Trading Up 247.7%

QURE stock opened at $47.50 on Thursday. The company's 50-day simple moving average is $15.90 and its 200-day simple moving average is $14.32. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a 52-week low of $4.45 and a 52-week high of $51.21. The firm has a market cap of $2.61 billion, a P/E ratio of -12.12 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. As a group, equities analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

Institutional Trading of uniQure

Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in uniQure in the 2nd quarter valued at about $117,000. Mraz Amerine & Associates Inc. acquired a new stake in uniQure in the 1st quarter valued at about $106,000. Teacher Retirement System of Texas acquired a new stake in uniQure in the 2nd quarter valued at about $151,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of uniQure during the 1st quarter worth approximately $152,000. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.